Industry Roundup: Supplement GMPs, Walgreens Recall, Healthy Children Study, Homeopathic Comments, Drug Claims
This article was originally published in The Tan Sheet
Executive Summary
Botanicals firm argues GMP intent; Walgreens multivitamin missing child-resistant capsWyeth Nutrition supports NIH healthy children study; homeopathic regulatory evaluation comment period extended; Vitamin Shoppe adds Beardall; and more news in brief.
You may also be interested in...
Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.